iCAD, Inc.: Business Overview, Financials & Competitive Analysis
iCAD, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage AI cancer detection play with meaningful clinical adoption but unproven path to profitability; restructuring bets on cloud transition success. iCAD demonstrates solid market positioning in a high-growth AI healthcare segment with global expansion potential and strong product-market fit. However, the company faces profitability challenges, a small market cap (~$108M).
What is iCAD, Inc.'s industry? iCAD, Inc. (icadmed.com) operates in Healthcare IT / AI Medical Imaging / Oncology Technology. AskCyborg classifies iCAD, Inc. under Healthcare IT / AI Medical Imaging / Oncology Technology in its company registry.
iCAD is a global leader in AI-powered cancer detection solutions, primarily focused on breast cancer screening through its ProFound Breast Health Suite. The company serves thousands of healthcare providers globally ac...
Cyborg Score thesis
Early-stage AI cancer detection play with meaningful clinical adoption but unproven path to profitability; restructuring bets on...
Read the full analyst-debate transcript →Get the Latest iCAD, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeiCAD, Inc. Overview
Pro stress-test →iCAD is a global leader in AI-powered cancer detection solutions, primarily focused on breast cancer screening through its ProFound Breast Health Suite. The company serves thousands of healthcare providers globally across over 50 countries, having processed more than 40 million mammograms in the last five years. iCAD is transitioning to a cloud-based SaaS business model to enhance financial predictability and scalability.
Strategic Profile
Pro stress-test →iCAD differentiates itself through clinically proven AI algorithms for early cancer detection and personalized risk assessment, with strong R&D backing evidenced by FDA clearances and partnerships with radiologists. The company is strategically pivoting from traditional software licensing to cloud-based recurring revenue models (ProFound Cloud), positioning itself for higher-margin, more predictable revenue streams in the growing AI healthcare market.
Competitive Landscape
Pro stress-test →iCAD competes in the AI-powered medical imaging market against larger players with broader oncology portfolios and against point-solution competitors. Key competitors include companies offering AI diagnostic tools for breast cancer, cardiology, and general radiology. iCAD's advantage lies in focused domain expertise in breast cancer detection and established relationships with radiologists globally, though it faces competition from well-funded AI healthcare startups and major healthcare IT vendors.
Industry Context
iCAD, Inc. operates in Healthcare IT / AI Medical Imaging / Oncology Technology.
Key facts
Founded: 1984 · Headquarters: Nashua, New Hampshire, US · Employees: Unknown · Revenue: $4.9M · Market cap: $108M